Antiplatelet  	Antiplatelet  	 NNP	B-NP
Therapy  	Therapy  	 NNP	I-NP
in  	in  	 IN	O
Carotid  	Carotid  	 NNP	B-NP
Artery  	Artery  	 NNP	I-NP
Stenting  	Stenting  	 NNP	I-NP
and  	and  	 CC	O
Carotid  	Carotid  	 NNP	B-NP
Endarterectomy  	Endarterectomy  	 NNP	I-NP
in  	in  	 IN	O
the  	the  	 DT	O
Asymptomatic  	Asymptomatic  	 NNP	B-NP
Carotid  	Carotid  	 NNP	I-NP
Surgery  	Surgery  	 NNP	I-NP
Trial-2  	Trial-2  	 NNP	I-NP
Strokes  	Strokes  	 NNS	I-NP
are  	are  	 VBP	O
infrequent  	infrequent  	 JJ	O
but  	but  	 CC	O
potentially  	potentially  	 RB	O
serious  	serious  	 JJ	B-NP
complications  	complications  	 NNS	I-NP
following  	following  	 VBG	O
carotid  	carotid  	 JJ	B-NP
intervention 	intervention 	 NN	I-NP
,  	,  	 ,	O
but  	but  	 CC	O
antiplatelet  	antiplatelet  	 JJ	B-NP
therapy  	therapy  	 NN	I-NP
can  	can  	 MD	O
reduce  	reduce  	 VB	O
these  	these  	 DT	O
risks 	risks 	 NNS	O
.  	.  	 .	O
There  	There  	 EX	O
are  	are  	 VBP	O
currently  	currently  	 RB	O
no  	no  	 DT	O
specific  	specific  	 JJ	O
guidelines  	guidelines  	 NNS	O
on  	on  	 IN	O
dose  	dose  	 NN	O
or  	or  	 CC	O
duration  	duration  	 NN	O
of  	of  	 IN	O
peri-procedural  	peri-procedural  	 JJ	B-NP
antiplatelet  	antiplatelet  	 JJ	I-NP
treatment  	treatment  	 NN	I-NP
for  	for  	 IN	O
patients  	patients  	 NNS	O
undergoing  	undergoing  	 VBG	O
carotid  	carotid  	 JJ	B-NP
intervention 	intervention 	 NN	I-NP
.  	.  	 .	O
Within  	Within  	 IN	O
the  	the  	 DT	O
ongoing  	ongoing  	 JJ	O
Asymptomatic  	Asymptomatic  	 NNP	B-NP
Carotid  	Carotid  	 NNP	I-NP
Surgery  	Surgery  	 NNP	I-NP
Trial-2  	Trial-2  	 NNP	I-NP
( 	( 	 -LRB-	O
ACST-2 	ACST-2 	 NNP	B-NP
) 	) 	 -RRB-	O
,  	,  	 ,	O
this  	this  	 DT	O
study  	study  	 NN	O
aimed  	aimed  	 VBN	O
at  	at  	 IN	O
assessing  	assessing  	 VBG	O
the  	the  	 DT	O
current  	current  	 JJ	O
use  	use  	 NN	O
of  	of  	 IN	O
antiplatelet  	antiplatelet  	 JJ	B-NP
therapy  	therapy  	 NN	I-NP
before 	before 	 RB	O
,  	,  	 ,	O
during 	during 	 IN	O
,  	,  	 ,	O
and  	and  	 CC	O
after  	after  	 IN	O
CEA  	CEA  	 NNP	B-NP
and  	and  	 CC	O
CAS  	CAS  	 NNP	B-NP
in  	in  	 IN	O
patients  	patients  	 NNS	O
with  	with  	 IN	O
asymptomatic  	asymptomatic  	 JJ	B-NP
carotid  	carotid  	 JJ	I-NP
stenosis 	stenosis 	 NN	I-NP
.  	.  	 .	O
Questionnaires  	Questionnaires  	 NNP	O
were  	were  	 VBD	O
sent  	sent  	 VBN	O
to  	to  	 TO	O
ACST-2  	ACST-2  	 CD	B-NP
collaborators  	collaborators  	 NNS	I-NP
seeking  	seeking  	 VBG	I-NP
information  	information  	 NN	I-NP
about  	about  	 IN	O
the  	the  	 DT	O
use  	use  	 NN	O
of  	of  	 IN	O
antiplatelet  	antiplatelet  	 JJ	B-NP
therapy  	therapy  	 NN	I-NP
during  	during  	 IN	O
the  	the  	 DT	O
pre- 	pre- 	 JJ	O
,  	,  	 ,	O
peri- 	peri- 	 NNP	O
,  	,  	 ,	O
and  	and  	 CC	O
post-operative  	post-operative  	 JJ	B-NP
periods  	periods  	 NNS	I-NP
in  	in  	 IN	O
patients  	patients  	 NNS	O
undergoing  	undergoing  	 VBG	O
carotid  	carotid  	 JJ	B-NP
intervention  	intervention  	 NN	I-NP
at  	at  	 IN	O
77  	77  	 CD	O
participating  	participating  	 VBG	B-NP
sites  	sites  	 NNS	I-NP
and  	and  	 CC	O
also  	also  	 RB	O
whether  	whether  	 IN	O
sites  	sites  	 NNS	O
tested  	tested  	 VBN	O
for  	for  	 IN	O
antiplatelet  	antiplatelet  	 JJ	B-NP
therapy  	therapy  	 NN	I-NP
resistance 	resistance 	 NN	I-NP
.  	.  	 .	O
The  	The  	 DT	O
response  	response  	 NN	B-NP
rate  	rate  	 NN	I-NP
was  	was  	 VBD	O
68 	68 	 CD	O
/ 	/ 	 CD	O
77  	77  	 CD	O
( 	( 	 -LRB-	O
88 	88 	 CD	O
% 	% 	 NN	O
) 	) 	 -RRB-	O
.  	.  	 .	O
For  	For  	 IN	O
CAS 	CAS 	 NNP	B-NP
,  	,  	 ,	O
82 	82 	 CD	O
%  	%  	 NN	O
of  	of  	 IN	O
sites  	sites  	 NNS	O
used  	used  	 VBN	O
dual  	dual  	 JJ	B-NP
antiplatelet  	antiplatelet  	 JJ	I-NP
therapy  	therapy  	 NN	I-NP
( 	( 	 -LRB-	O
DAPT 	DAPT 	 NNP	B-NP
)  	)  	 -RRB-	O
pre-operatively  	pre-operatively  	 JJ	B-NP
and  	and  	 CC	O
86 	86 	 CD	O
%  	%  	 NN	O
post-operatively  	post-operatively  	 NN	B-NP
with  	with  	 IN	O
a  	a  	 DT	O
mean  	mean  	 JJ	O
post-procedural  	post-procedural  	 JJ	B-NP
duration  	duration  	 NN	I-NP
of  	of  	 IN	O
3  	3  	 CD	O
months  	months  	 NNS	O
( 	( 	 -LRB-	O
range  	range  	 NN	O
1-12 	1-12 	 CD	O
) 	) 	 -RRB-	O
,  	,  	 ,	O
while  	while  	 IN	O
9 	9 	 CD	O
%  	%  	 NN	O
continued  	continued  	 VBD	B-NP
DAPT  	DAPT  	 NNP	I-NP
life-long 	life-long 	 NNP	I-NP
.  	.  	 .	O
For  	For  	 IN	O
CEA  	CEA  	 NNP	B-NP
only  	only  	 RB	O
31 	31 	 CD	O
%  	%  	 NN	O
used  	used  	 VBD	O
DAPT  	DAPT  	 NNP	B-NP
pre-operatively 	pre-operatively 	 NNP	I-NP
,  	,  	 ,	O
24 	24 	 CD	O
%  	%  	 NN	O
post-operatively  	post-operatively  	 NN	B-NP
with  	with  	 IN	O
a  	a  	 DT	O
mean  	mean  	 JJ	O
post-procedural  	post-procedural  	 JJ	B-NP
duration  	duration  	 NN	I-NP
of  	of  	 IN	O
3  	3  	 CD	O
months  	months  	 NNS	O
( 	( 	 -LRB-	O
range  	range  	 NN	O
1-5 	1-5 	 CD	O
) 	) 	 -RRB-	O
,  	,  	 ,	O
while  	while  	 IN	O
10 	10 	 CD	O
%  	%  	 NN	O
continued  	continued  	 VBD	B-NP
DAPT  	DAPT  	 NNP	I-NP
life-long 	life-long 	 NNP	I-NP
.  	.  	 .	O
For  	For  	 IN	O
those  	those  	 DT	O
prescribing  	prescribing  	 FW	O
post-procedural  	post-procedural  	 FW	B-NP
mono  	mono  	 FW	I-NP
antiplatelet  	antiplatelet  	 FW	I-NP
( 	( 	 -LRB-	O
MAPT 	MAPT 	 NNP	B-NP
)  	)  	 -RRB-	O
therapy  	therapy  	 NN	O
( 	( 	 -LRB-	O
76 	76 	 CD	O
% 	% 	 NN	O
) 	) 	 -RRB-	O
,  	,  	 ,	O
aspirin  	aspirin  	 NN	O
was  	was  	 VBD	O
more  	more  	 RBR	O
commonly  	commonly  	 RB	O
prescribed  	prescribed  	 VBN	O
( 	( 	 -LRB-	O
59 	59 	 CD	O
% 	% 	 NN	O
)  	)  	 -RRB-	O
than  	than  	 IN	O
clopidogrel  	clopidogrel  	 NNS	B-NP
( 	( 	 -LRB-	O
6 	6 	 CD	O
% 	% 	 NN	O
)  	)  	 -RRB-	O
and  	and  	 CC	O
11 	11 	 CD	O
%  	%  	 NN	O
of  	of  	 IN	O
centres  	centres  	 NN	O
did  	did  	 VBD	O
not  	not  	 RB	O
show  	show  	 VB	O
a  	a  	 DT	O
preference  	preference  	 NN	O
for  	for  	 IN	O
either  	either  	 DT	O
aspirin  	aspirin  	 NN	O
or  	or  	 CC	O
clopidogrel 	clopidogrel 	 NN	B-NP
.  	.  	 .	O
Eleven  	Eleven  	 JJ	O
centres  	centres  	 NNS	O
( 	( 	 -LRB-	O
16 	16 	 CD	O
% 	% 	 NN	O
)  	)  	 -RRB-	O
tested  	tested  	 VBN	O
for  	for  	 IN	O
antiplatelet  	antiplatelet  	 JJ	B-NP
therapy  	therapy  	 NN	I-NP
resistance 	resistance 	 NN	I-NP
.  	.  	 .	O
There  	There  	 EX	O
appears  	appears  	 VBZ	O
to  	to  	 TO	O
be  	be  	 VB	O
broad  	broad  	 JJ	O
agreement  	agreement  	 NN	O
on  	on  	 IN	O
the  	the  	 DT	O
use  	use  	 NN	O
of  	of  	 IN	O
antiplatelet  	antiplatelet  	 JJ	B-NP
therapy  	therapy  	 NN	I-NP
in  	in  	 IN	O
ACST-2  	ACST-2  	 CD	B-NP
patients  	patients  	 NNS	I-NP
undergoing  	undergoing  	 VBG	O
carotid  	carotid  	 JJ	B-NP
artery  	artery  	 NN	I-NP
stenting  	stenting  	 NNS	I-NP
and  	and  	 CC	O
surgery 	surgery 	 NN	O
.  	.  	 .	O
Although  	Although  	 IN	O
evidence  	evidence  	 NN	O
to  	to  	 TO	O
help  	help  	 VB	O
guide  	guide  	 VB	O
the  	the  	 DT	O
duration  	duration  	 NN	O
of  	of  	 IN	O
peri-procedural  	peri-procedural  	 JJ	B-NP
antiplatelet  	antiplatelet  	 JJ	I-NP
therapy  	therapy  	 NN	I-NP
is  	is  	 VBZ	O
limited 	limited 	 VBN	O
,  	,  	 ,	O
long-term  	long-term  	 JJ	O
treatment  	treatment  	 NN	O
with  	with  	 IN	O
DAPT  	DAPT  	 NNP	B-NP
appears  	appears  	 VBZ	O
similar  	similar  	 JJ	O
between  	between  	 IN	O
both  	both  	 DT	O
treatment  	treatment  	 NN	B-NP
arms 	arms 	 NNS	I-NP
.  	.  	 .	O
